• Latest Posts

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

What’s in the Cards for a Biosimilar after it Launches

Boehringer enters the Biosimilar War against Blockbuster Humira

Biosimilars are all the rage, but how do they compare to Generics?

Top 10 Best-selling Biologicals of 2015

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen


The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran

Cinfa Biotech’s Biosimilar is on the Starting Block!

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history